Skip to main content
. Author manuscript; available in PMC: 2013 Nov 1.
Published in final edited form as: Lancet Neurol. 2012 Oct 4;11(11):963–972. doi: 10.1016/S1474-4422(12)70213-2

Table 4.

Prediction of clinico-radiological disease activity & disability progression with baseline INL thicknesses in MS

Univariate Model1 Multivariate Model1,2
Odds ratio per 5μm increase in INL thickness in RRMS (95%CI) p-value Odds ratio per 5μm increase in INL thickness in all MS (95%CI) p-value Odds ratio per 5μm increase in INL thickness in RRMS (95%CI) p-value Odds ratio per 5μm increase in INL thickness in all MS (95%CI) p-value
Non-ocular relapse 1·76 (1·16–2·67) 0·008 1·77 (1·14–2·74) 0·01
EDSS progression3,4 1·48 (1·02–2·15) 0.039 1·41 (1·03–1·95) 0·034 1·49 (1·01–2·21) 0·047 1·40 (1·001–1·94) 0·049
New Gd-enhancing lesion5 1·90 (1·24–2·90) 0·003 1·70 (1·16–2·50) 0·007 1·98 (1·29–3·03) 0·002 1·71 (1·16–2·52) 0·007
New T2 lesion5 1·59 (1·08–2·34) 0·020 1·51 (1·08–2·09) 0·015 1·56 (1·03–2·37) 0·035 1·46 (1·05–2·02) 0·025
Relapse or New Gd-enhancing lesion5 1·92 (1·27–2·90) 0·002 1·95 (1·27–2·99) 0·002

INL: inner nuclear layer; RRMS: relapsing remitting multiple sclerosis; EDSS: expanded disability status scale; CI: confidence intervals;

1

Adjusted for within-subject inter eye correlation

2

Additionally adjusted for age, sex, disease duration and history of optic neuritis

3

EDSS progression defined as a ≥1-point increase if baseline EDSS < 6·0 and a ≥0·5 point increase if baseline EDSS ≥ 6·0

4

Available for 118 RRMS, 25 SPMS and 14 PPMS patients

5

Available for 120 RRMS, 24 SPMS and 14 PPMS patients